Corelattions Between CD31, CD68, MMP-2 and MMP-9 Expression in Allograft Cardiac Rejection – Immunohistochemical Study

1. Mangiola M, Marrari M, Feingold B, Zeevi A. Significance of Anti-HLA Antibodies on Adult and Pediatric Heart Allograft Outcomes. Frontiers in Immunology. 2017;8(4).10.3389/fimmu.2017.00004526944828191005Search in Google Scholar

2. Freystaetter K, Andreas M, Bilban M, Perkmann T, Kaider A, Masetti M, et al. The recipient’s heme oxygenase-1 promoter region polymorphism is associated with cardiac allograft vasculopathy. Transpl Int. 2017;30(5):510-8.10.1111/tri.1293528186648Search in Google Scholar

3. Nakamura K, Inami M, Morio H, Okuma K, Ito M, Noto T, et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. European Journal of Pharmacology. 2017;796:69-75.10.1016/j.ejphar.2016.12.02527993641Search in Google Scholar

4. Colvin Monica M, Cook Jennifer L, Chang P, Francis G, Hsu Daphne T, Kiernan Michael S, et al. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management. Circulation. 2015;131(18):1608-39.10.1161/CIR.000000000000009325838326Search in Google Scholar

5. Polyakova V, Hein S, Kostin S, Ziegelhoeffer T, Schaper J. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. Journal of the American College of Cardiology. 2004;44(8):1609-18.10.1016/j.jacc.2004.07.02315489093Search in Google Scholar

6. Aharinejad S, Krenn K, Zuckermann A, Schäfer R, Gmeiner M, Thomas A, et al. Serum Matrix Metalloprotease-1 and Vascular Endothelial Growth Factor–A Predict Cardiac Allograft Rejection. American Journal of Transplantation. 2009;9(1):149-59.10.1111/j.1600-6143.2008.02470.x19067665Search in Google Scholar

7. Calé R, Almeida M, Gonçalves P, Rebocho MJ, Raposo L, Teles R, et al. Complicações da biópsia endomiocárdica após transplante cardíaco. Um mal menor. Revista Portuguesa de Cardiologia. 2012;31(2):159-62.10.1016/j.repc.2011.12.00622222062Search in Google Scholar

8. Michel RP, Berry GJ. Pathology of Transplantation: A Practical Diagnostic Approach: Springer International Publishing; 2016.10.1007/978-3-319-29683-8Search in Google Scholar

9. Buszko M, Cardini B, Oberhuber R, Oberhuber L, Jakic B, Beierfuß A, et al. Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3Ɛ humanized mice treated with polyclonal anti human thymocyte globulin. PLOS ONE. 2017;12:e0173088.10.1371/journal.pone.0173088533625428257450Search in Google Scholar

10. Deng MC. The AlloMap™ genomic biomarker story: 10 years after. Clinical Transplantation. 2017;31(3):e12900.10.1111/ctr.1290028256042Search in Google Scholar

11. Yerly P RS, Nobile A, Aubert V, Tozzi PG, Yarol N, Vogt P, Hullin R & Pascual M. Time-Dependent Specificity of Immunopathologic (C4d-CD68) and Histologic Criteria of Antibody-Mediated Rejection for Donor-Specific Antibodies and Allograft Dysfunction in Heart Transplantation. Transplantation. 2015;99(3):586-93.10.1097/TP.000000000000024624983305Search in Google Scholar

12. Li L, Duan X, Wang H, Wang Q, Lu Y, Yan C, et al. Acute cellular rejection and antibody-mediated rejection in endomyocardial biopsy after heart transplantation: A retrospective study from a single medical center. International Journal of Clinical and Experimental Pathology. 2017;10:4772-9.Search in Google Scholar

13. Bayliss J BM, Leet A, Stein AN, Thomson NM & McLean CA.. Late onset antibody mediated rejection and endothelial localization of vascular endothelial growth factor are associated with development of cardiac allograft vasculopathy. Transplantation. 2008;86(7): 991-7.10.1097/TP.0b013e318186d73418852667Search in Google Scholar

14. Cheung K, Ma L, Wang G, Coe D, Ferro R, Falasca M, et al. CD31 signals confer immune privilege to the vascular endothelium. Proceedings of the National Academy of Sciences. 2015;112(43):E5815..10.1073/pnas.1509627112462937926392551Search in Google Scholar

15. Di Francesco A, Fedrigo M, Santovito D, Natarelli L, Castellani C, De Pascale F, et al. MicroRNA signatures in cardiac biopsies and detection of allograft rejection. The Journal of Heart and Lung Transplantation. 2018;37(11):1329-40.10.1016/j.healun.2018.06.01030174164Search in Google Scholar

16. Suzuki J-i, Isobe M, Kawauchi M, Endoh M, Amano J, Takamoto S. Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transpl Int. 2000;13(2):106-13.10.1111/j.1432-2277.2000.tb01049.xSearch in Google Scholar

17. Campbell LG, Ramachandran S, Liu W, Shipley JM, Itohara S, Rogers JG, et al. Different Roles for Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in the Pathogenesis of Cardiac Allograft Rejection. American Journal of Transplantation. 2005;5(3):517-28.10.1111/j.1600-6143.2005.00744.x15707406Search in Google Scholar

18. Vanhoutte D, van Almen GC, Van Aelst LN, Van Cleemput J, Droogne W, Jin Y, et al. Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection. Eur Heart J. 2013 Jul;34(25):1930-41.10.1093/eurheartj/ehs375405125923139380Search in Google Scholar